- Home
- Products
- Customized ADCs
- CA9
- Anti-CA9 (Girentuximab)-MC-Vc-PAB-MMAE ADC
Anti-CA9 (Girentuximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-743)
This ADC product is comprised of an anti-CA9 monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CA9
- Alternative Names
- CA9; carbonic anhydrase IX; carbonic anhydrase 9; CAIX; carbonic dehydratase; MN; RCC associated protein G250; pMW1; CA-IX; P54/58N; membrane antigen MN; carbonate dehydratase IX; RCC-associated antigen G250; RCC-associated protein G250; renal cell carcin
- Target Entrez Gene ID
- 768
- Target UniProt ID
- Q16790
- Overview
- Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12.
- Overview
- Chimeric Anti-CA9 IgG1-kappa antibody, Girentuximab
- Generic name
- Girentuximab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-743. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-744 | Anti-CA9 (Girentuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-742 | Anti-CA9 (Girentuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-475 | Anti-CA9-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-741 | Anti-CA9 (Girentuximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-745 | Anti-CA9 (Girentuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2596 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2586 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2574 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2540 | Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2580 | Anti-CEACAM5-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2568 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2529 | Anti-CD22-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-integrin alpha(v)beta(3) (Etaracizumab)-MC-MMAF ADC (CAT#: ADC-W-1498)
- Anti-FOLH1-VC-MMAE ADC (CAT#: ADC-W-470)
- Anti-EGFR (Modotuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2341)
- Anti-CD22-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2530)
- Anti-MUC1 (Nacolomab tafenatox)-MC-MMAF ADC (CAT#: ADC-W-1630)
- Anti-ITGAV-DM4 ADC (CAT#: ADC-W-109)
- Anti-GPC3 (Codrituzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2322)
- Anti-IGF2 (Dusigitumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1271)
- Anti-IL17RA (Brodalumab)-SPDB-DM4 ADC (CAT#: ADC-W-1317)
- Anti-IGF2 (Dusigitumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1272)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
